Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALNY

Alnylam Pharmaceuticals Inc

Nov 29 • 09:59AM ET

163.48

Dollar change +2.12
Percentage change 1.31	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.15	Insider Own	0.42%	Shs Outstand	125.49M	Perf Week	-0.12%
Market Cap	20.52B	Forward P/E	-	EPS next Y	-4.32	Insider Trans	-4.64%	Shs Float	124.97M	Perf Month	7.97%
Income	-509.87M	PEG	-	EPS next Q	-1.20	Inst Own	94.68%	Short Float / Ratio	4.16% / 7.77	Perf Quarter	-15.93%
Sales	1.72B	P/S	11.90	EPS this Y	59.42%	Inst Trans	0.96%	Short Interest	5.19M	Perf Half Y	-12.32%
Book/sh	-1.32	P/B	-	EPS next Y	-14.56%	ROA	-13.83%	Target Price	225.66	Perf Year	-23.15%
Cash/sh	19.18	P/C	8.53	EPS next 5Y	-	ROE	-1500.66%	52W Range	148.10 - 242.97	Perf YTD	-31.21%
Dividend	-	P/FCF	-	EPS past 5Y	-11.39%	ROI	-21.13%	52W High	-32.72%	Beta	0.48
Dividend %	-	Quick Ratio	3.04	Sales past 5Y	79.03%	Gross Margin	84.00%	52W Low	10.38%	ATR	5.56
Employees	2002	Current Ratio	3.14	Sales Q/Q	183.96%	Oper. Margin	-20.56%	RSI (14)	48.00	Volatility	3.00% 3.70%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	134.66%	Profit Margin	-29.58%	Rel Volume	0.92	Prev Close	161.36
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 02 BMO	Payout	-	Avg Volume	668.65K	Price	163.48
Recom	1.66	SMA20	-0.47%	SMA50	-1.94%	SMA200	-13.45%	Volume	73,921	Change	1.31%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$175
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$210 → $178
Mar-01-22	Initiated	Citigroup	Buy	$223
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy	$170
Jan-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$181 → $208
Nov-22-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$144 → $225
Nov-22-21	Upgrade	Goldman	Neutral → Buy	$273
Nov-01-21	Upgrade	Oppenheimer	Perform → Outperform	$200
Oct-04-21	Upgrade	UBS	Neutral → Buy	$141 → $215
Aug-04-21	Downgrade	Piper Sandler	Overweight → Neutral	$45 → $47
Feb-22-21	Downgrade	Guggenheim	Buy → Neutral	$162

Show Previous Ratings

Nov-11-23 04:00PM	Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk (Business Wire)
Nov-09-23 09:25AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Nov-08-23 09:55AM	Wall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a Bet (Zacks)
Nov-07-23 08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Nov-04-23 01:08PM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call Transcript (Insider Monkey)
11:47AM	Loading…
Nov-03-23 11:47AM	Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues (Zacks)
11:06AM	Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales (Zacks)
Nov-02-23 10:09AM	Alnylam Pharmaceuticals Inc (ALNY) Reports 35% YoY Growth in Q3 2023 Net Product Revenues (GuruFocus.com)
10:00AM	Alnylam (ALNY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:12AM	Alnylam: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity (Business Wire)
Oct-26-23 02:00PM	Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year (Business Wire)
10:02AM	Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline (Zacks)
Oct-25-23 05:19PM	Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine (Business Wire)
11:05AM	Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimers Disease and Cerebral Amyloid Angiopathy (Business Wire)
07:28PM	Loading…
Oct-19-23 07:28PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
08:00AM	Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results (Business Wire)
Oct-12-23 08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-10-23 10:24AM	Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro (Zacks)
Oct-09-23 04:35PM	Tesla, Bristol Myers-Mirati deal, Alnylam Pharma: Top Tickers (Yahoo Finance Video)
04:08PM	Alnylam Is Now 'One Of The Most Binary' Stories In Biotech. Why The FDA Rejected Its Heart Drug. (Investor's Business Daily)
10:34AM	Alnylam Stock Is Dropping on Surprising FDA Rejection (Barrons.com)
10:19AM	Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug (Investor's Business Daily)
07:49AM	UPDATE 2-Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval (Reuters)
07:36AM	US FDA declines to approve expanded use of Alnylam's heart-disease drug (Reuters)
07:30AM	Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire)
Oct-08-23 06:29AM	2 Growth Stocks That Could Rocket Higher Before the End of 2023 (Motley Fool)
Oct-06-23 07:00AM	Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023 (Business Wire)
Sep-20-23 12:12PM	13 Best Beaten Down Stocks To Buy Now (Insider Monkey)
04:07PM	Loading…
Sep-14-23 04:07PM	Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer (Investor's Business Daily) -8.78%
09:36AM	Alnylam's (ALNY) Onpattro sNDA Gets FDA Advisory Committee Nod (Zacks)
Sep-13-23 06:24PM	U.S. FDA panel backs expanded use of Alnylam's gene silencing drug (Reuters)
04:57PM	Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire)
08:08AM	Buy List Alert: 3 Pharma Stocks with Positive Trial Updates (InvestorPlace)
07:00AM	Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire)
Sep-08-23 09:58AM	Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More (Zacks)
06:52AM	Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study (Zacks)
Sep-07-23 11:30AM	Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report? (Zacks)
07:22AM	UPDATE 2-Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial (Reuters)
07:08AM	Alnylam hypertension drug meets main goal in mid-stage study (Reuters)
07:00AM	Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk (Business Wire)
Sep-06-23 11:30AM	CRISPR Therapeutics AG (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound? (Zacks)
03:00AM	First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals (Business Wire)
Aug-27-23 09:31AM	18 Best 52-Week Low Stocks To Buy Now (Insider Monkey)
Aug-25-23 06:35PM	UPDATE 1-Alnylam to appeal ruling on patents related to Moderna's COVID vaccines (Reuters)
06:02PM	Alnylam to appeal ruling on patents related to Moderna's COVID vaccines (Reuters)
05:00PM	Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna (Business Wire)
Aug-15-23 09:15AM	Apellis (APLS) Focuses on Empaveli to Fuel Its Growth (Zacks)
Aug-10-23 06:08AM	The Petri Dish: Agios licenses Alnylam drug, Ikena acquires startup with Gilead stake (American City Business Journals)
Aug-08-23 06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-06-23 07:26PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Aug-04-23 11:24AM	Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss (Zacks)
09:53AM	Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Profit Outlook (Simply Wall St.)
Aug-03-23 11:53PM	Q2 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
11:00AM	Alnylam (ALNY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:15AM	Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:05AM	Alnylam: Q2 Earnings Snapshot (AP Finance)
08:00AM	Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity (Business Wire)
Aug-02-23 08:30AM	Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-27-23 05:14AM	UPDATE 1-Roche CFO flags need to bolster late-stage drug development (Reuters)
Jul-24-23 02:07PM	Alnylam, Roche team up in $3B+ deal over hypertension drug (American City Business Journals)
01:20PM	Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche (Zacks)
01:13AM	Roche enters partnership with Alnylam for hypertension therapy (Reuters)
01:00AM	Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk (Business Wire)
Jul-21-23 10:44AM	Why Shares of BridgeBio Pharma Skyrocketed This Week (Motley Fool)
Jul-20-23 10:02AM	Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know (Zacks)
08:11AM	Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio (Zacks)
08:00AM	Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results (Business Wire)
Jul-19-23 05:00PM	Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine (Business Wire)
Jul-17-23 06:29PM	Why Alnylam Pharmaceuticals Topped the Market Today (Motley Fool)
04:07PM	BridgeBio Launches 76% And Pulls Its Rival Higher On Bullish Heart Drug News (Investor's Business Daily)
12:29PM	BridgeBio Launches 80% And Pulls Its Rivals Higher On Bullish Heart Drug News (Investor's Business Daily)
10:13AM	BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease (Investor's Business Daily)
10:06AM	Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study (Zacks)
06:59AM	BridgeBio unveils positive results from rare heart disease drug trial, shares jump (Investing.com)
02:21AM	Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimers Disease and Cerebral Amyloid Angiopathy (Business Wire)
Jul-03-23 10:25AM	Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date (Zacks)
Jun-30-23 09:00AM	Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis (Business Wire)
Jun-05-23 04:00PM	Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-01-23 06:22AM	Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares (Simply Wall St.)
May-26-23 04:55PM	Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines (Reuters)
May-22-23 12:01PM	Alnylam (ALNY) Reports Positive Results From APOLLO-B Study (Zacks)
May-20-23 10:50AM	Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (Business Wire)
May-09-23 02:59PM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-05-23 03:44PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
12:35PM	Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues (Zacks)
06:03AM	Alnylam Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-04-23 09:15AM	Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Alnylam: Q1 Earnings Snapshot (AP Finance)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity (Business Wire)
May-03-23 04:00PM	Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference (Business Wire)
08:00AM	Alnylam Issues 2022 Corporate Responsibility Report (Business Wire)
Apr-27-23 01:52PM	Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says (Benzinga)
10:02AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-26-23 08:18PM	UPDATE 1-Second judge says US not liable in Moderna COVID-19 vaccine patent case (Reuters)
06:59PM	Second judge says US not liable in Moderna COVID-19 vaccine patent case (Reuters)
04:05PM	Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimers Disease and Cerebral Amyloid Angiopathy (GlobeNewswire)
04:05PM	Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimers Disease and Cerebral Amyloid Angiopathy (Business Wire)
Apr-24-23 03:55PM	3 Pharma Stocks That Could See a Surge in Demand in 2023 (InvestorPlace)

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garg Pushkal	CMO & EVP Dev & Med Affairs	Aug 07	Sale	183.89	4,166	766,083	4,345	Aug 07 06:05 PM
Vaishnaw Akshay	President	Aug 04	Sale	185.85	4,057	753,986	22,774	Aug 07 06:04 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 04	Sale	185.85	4,057	753,986	35,216	Aug 07 06:04 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Aug 04	Sale	185.85	3,461	643,223	8,511	Aug 07 06:05 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Aug 04	Sale	185.85	3,460	643,037	15,873	Aug 07 06:05 PM
BONNEY MICHAEL W	Director	Aug 03	Sale	185.38	6,448	1,195,310	16,029	Aug 04 04:02 PM
BONNEY MICHAEL W	Director	Aug 02	Option Exercise	0.00	22,477	0	22,477	Aug 04 04:02 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Apr 28	Sale	199.02	2,455	488,595	4,345	Apr 28 05:54 PM
Greenstreet Yvonne	Chief Executive Officer	Apr 27	Sale	194.59	7,615	1,481,811	30,332	Apr 28 05:55 PM
Vaishnaw Akshay	President	Apr 27	Sale	194.59	2,392	465,464	17,890	Apr 28 05:54 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Apr 27	Sale	194.59	1,839	357,855	6,800	Apr 28 05:54 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Apr 27	Sale	194.59	1,476	287,215	1,801	Apr 28 05:55 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Apr 27	Sale	194.59	977	190,113	11,706	Apr 28 05:55 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Apr 06	Sale	210.00	3,500	735,000	0	Apr 10 04:29 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03	Option Exercise	96.45	5,000	482,250	22,417	Mar 07 04:07 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03	Sale	200.00	18,072	3,614,400	4,345	Mar 07 04:07 PM
SCHULMAN AMY W	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:13 PM
HAMBURG MARGARET A	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:12 PM
PYOTT DAVID E I	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:13 PM
Ausiello Dennis A	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:11 PM
Fanucci Marsha	Director	Feb 23	Option Exercise	0.00	136	0	136	Feb 27 04:11 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 03	Sale	232.14	3,424	794,854	0	Feb 03 05:45 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 02	Sale	226.01	1,675	378,563	3,500	Feb 03 05:46 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 02	Sale	226.01	1,601	361,839	3,424	Feb 03 05:45 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 01	Option Exercise	0.00	5,025	0	5,025	Feb 03 05:45 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 01	Option Exercise	0.00	5,175	0	5,175	Feb 03 05:46 PM
Vaishnaw Akshay	President	Dec 05	Option Exercise	59.05	5,079	299,938	23,425	Dec 07 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your FINVIZ experience